drugset

drugset / Trial / NCT00578916

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

NCT00578916 ↗

Phase 1 Completed 17 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.

Timeline

Start: 2008-01
Primary completion: 2008-01
Completion: 2008-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-690514	Small molecule	200 mg	Oral

Indications